Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | APLNR | P35414 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294941 | 0.93 | LMNA (0.48) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL17298088 | 0.92 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL19095398 | 0.92 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL19095401 | 0.91 | APLNR (0.47) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL17298103 | 0.91 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL19095406 | 0.91 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL17298082 | 0.91 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL19104702 | 0.91 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL19095404 | 0.90 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL17295003 | 0.89 | ALDH1A1 (0.45) | LMNASMN1; SMN2KDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-06-03 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | LMNA 2152/4885SMN1; SMN2 4551/4885KDM4E 4185/4885 |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | LMNA 2152/4885SMN1; SMN2 4551/4885KDM4E 4185/4885 |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | LMNA 2152/4885SMN1; SMN2 4551/4885KDM4E 4185/4885 |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | LMNA 2152/4885SMN1; SMN2 4551/4885KDM4E 4185/4885 |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | LMNA 2152/4885SMN1; SMN2 4551/4885KDM4E 4185/4885 |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | LMNA 2152/4885SMN1; SMN2 4551/4885KDM4E 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.